| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 04/03/2003 | US20030064919 Novel polypeptides and polynucleotides encoding same |
| 04/03/2003 | US20030064410 Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids |
| 04/03/2003 | US20030064369 Novel proteins and nucleic acids encoding same |
| 04/03/2003 | US20030064121 For use as dietary supplement, in drugs, soy protein concentrate |
| 04/03/2003 | US20030064098 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 04/03/2003 | US20030064097 For delivery of drugs, nutrionals, cosmeceuticals and diagnostic agents |
| 04/03/2003 | US20030064063 For prophylaxis of type I hypersensitivity disease in a subject receiving immunotherapy |
| 04/03/2003 | US20030064052 Useful for maintaining controlled and reliable dosage of the therapeutic agent via pulmonary delivery |
| 04/03/2003 | CA2688860A1 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| 04/03/2003 | CA2469230A1 Antibody inhibitors of gdf-8 and uses thereof |
| 04/03/2003 | CA2463039A1 1,6-naphthyridine derivatives as antidiabetics |
| 04/03/2003 | CA2461861A1 Stem cells of the islets of langerhans and their use in treating diabetes mellitus |
| 04/03/2003 | CA2461801A1 Sphingolipids |
| 04/03/2003 | CA2461693A1 Dosage form for treatment of diabetes mellitus |
| 04/03/2003 | CA2461666A1 Combination therapies for immune mediated diseases |
| 04/03/2003 | CA2461563A1 Flavonoids for treatment of diabetes |
| 04/03/2003 | CA2461454A1 Assessment of neurons in the arcuate nucleus to screen for agents that modify feeding behavior |
| 04/03/2003 | CA2461372A1 Dna sequences for human angiogenesis genes |
| 04/03/2003 | CA2461345A1 Use of pyy or agonist thereof to modify feeding behaviour |
| 04/03/2003 | CA2461144A1 Preparation and use of pyrrole derivatives for treating obesity |
| 04/03/2003 | CA2461142A1 Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity |
| 04/03/2003 | CA2461136A1 A method of reducing the in vivo cholesterol ester transfer protein mediated transfer of cholesteryl esters between high density lipoproteins (hdl) and low density lipoproteins (ldl) |
| 04/03/2003 | CA2461132A1 1, 8-naphthyridine derivatives as antidiabetics |
| 04/03/2003 | CA2461095A1 Process for making substituted pyrazoles |
| 04/03/2003 | CA2461087A1 Process for the preparation of repaglinide |
| 04/03/2003 | CA2460953A1 Proteins associated with cell growth, differentiation, and death |
| 04/03/2003 | CA2460000A1 Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma |
| 04/03/2003 | CA2459999A1 Antagonists_and agonists of igf-1 receptor |
| 04/03/2003 | CA2459943A1 Androstanes as androgen receptor modulators |
| 04/03/2003 | CA2459926A1 Screening and selection methods for statin drug combinations |
| 04/03/2003 | CA2459789A1 3-desoxy-vitamin d3 analog esters |
| 04/03/2003 | CA2458661A1 Methods of increasing endogenous testosterone levels |
| 04/03/2003 | CA2458279A1 Modulation of vitamin storage |
| 04/03/2003 | CA2453985A1 Receptors and membrane-associated proteins |
| 04/03/2003 | CA2424770A1 Solid pharmaceutical preparation |
| 04/02/2003 | WO2002030891A1 Aliphatic nitrogenous five-membered ring compounds |
| 04/02/2003 | WO2002028821A2 Propionic acid derivatives with ppar-alpha activating properties |
| 04/02/2003 | EP1298348A1 Bush, group of bush, suspension cross-member, vehicle, method for mounting a bush and method for mounting a group of bushes |
| 04/02/2003 | EP1298223A2 Methods related to the A-C repeat Z-sequence upstream from the aldose reductase gene |
| 04/02/2003 | EP1298203A2 Diagnosis and treatment of autoimmune diseases |
| 04/02/2003 | EP1297842A1 Medicinal components comprising human parathyroid hormone and medicinal compositions for nasal administration containing the components |
| 04/02/2003 | EP1297841A1 Pancreatic langerhans beta cell proliferation promoter and apoptosis inhibitor, and screening of candidate compounds for the e drugs |
| 04/02/2003 | EP1297833A1 Indole carboxylic acids as thyroid receptor ligands |
| 04/02/2003 | EP1297139A2 G-protein coupled receptor org10 |
| 04/02/2003 | EP1297135A2 Pd-l2 molecules: novel pd-1 ligands and uses therefor |
| 04/02/2003 | EP1297130A2 G-protein coupled receptors |
| 04/02/2003 | EP1297127A2 Gpr22 modulators as appetite-control agents |
| 04/02/2003 | EP1297014A2 Transporters and ion channels |
| 04/02/2003 | EP1297012A2 Novel fibroblast growth factors and nucleic acids encoding same |
| 04/02/2003 | EP1296996A1 Purine derivatives |
| 04/02/2003 | EP1296981A2 Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors |
| 04/02/2003 | EP1296980A1 Thiazolidinedione salt for treatment of diabetes mellitus |
| 04/02/2003 | EP1296976A1 Novel 1,3-dihydro-2h-indol-one derivatives, method for preparing same and pharmaceutical compositions containing them |
| 04/02/2003 | EP1296975A1 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors |
| 04/02/2003 | EP1296974A2 2-cyanopyrrolidine derivatives and their use as medicaments |
| 04/02/2003 | EP1296967A1 Quinolinyl and benzothiazolyl ppar-gamma modulators |
| 04/02/2003 | EP1296943A1 Amino acid derivatives and their use as medicines |
| 04/02/2003 | EP1296942A1 Glucagon antagonists/inverse agonists |
| 04/02/2003 | EP1296936A1 Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones |
| 04/02/2003 | EP1296934A1 Cyclohexylamine derivatives as subtype selective nmda receptor antagonists |
| 04/02/2003 | EP1296929A2 Modified forms of pharmacologically active agents and uses therefor |
| 04/02/2003 | EP1296742A1 Needle for intradermal delivery of substances having penetration limiting means |
| 04/02/2003 | EP1296740A1 Microneedle for delivering a substance into the dermis |
| 04/02/2003 | EP1296723A1 A medicinal aerosol formulation |
| 04/02/2003 | EP1296716A2 New formulation |
| 04/02/2003 | EP1296709A1 Solubilised protein vaccines |
| 04/02/2003 | EP1296699A1 Therapeutic agents - iii |
| 04/02/2003 | EP1296698A1 Therapeutic agents - ii |
| 04/02/2003 | EP1296697A1 Therapeutic agents - i |
| 04/02/2003 | EP1296681A2 Use of microsomal triglyceride transfer protein (mtp) inhibitors for reducing the number of postprandial triglyceride-rich lipoprotein particles (pptrl) |
| 04/02/2003 | EP1296674A2 Use of substituted indole compounds for increasing nitric oxide synthase activity |
| 04/02/2003 | EP1296670A1 Therapeutic combinations of fatty acids |
| 04/02/2003 | EP1296660A1 The controlled release preparation of insulin and its method |
| 04/02/2003 | EP1296657A1 Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates |
| 04/02/2003 | EP1296648A1 Micellar pharmaceutical compositions for buccal and pulmonary application |
| 04/02/2003 | EP1296646A2 Oral pharmaceutical compositions containing terbinafine |
| 04/02/2003 | EP1296590A2 A personal condition management system |
| 04/02/2003 | EP1296552A2 Erk-5 deficient animals and methods of inhibiting angiogenesis through the inhibition of erk-5 |
| 04/02/2003 | EP1226143B1 Imidazopyridine derivatives used as phosphodiesterase vii inhibitors |
| 04/02/2003 | EP1135126A4 Myt1 kinase inhibitors |
| 04/02/2003 | EP1114051B1 INHIBITORS OF p38 |
| 04/02/2003 | EP1096940B1 Biocompatible and biodegradable compositions containing hyaluronic acid and the derivatives thereof for the treatment of ulcers in the digestive apparatus |
| 04/02/2003 | EP1043993B1 Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men and method to study the dyssynergia in male rodents |
| 04/02/2003 | EP1021456B1 Macrocyclic 13-membered ring derivatives of erythromycins a and b |
| 04/02/2003 | EP0954519B1 Alpha-9 integrin antagonists and anti-inflammatory compositions therof |
| 04/02/2003 | EP0894089B9 Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them |
| 04/02/2003 | EP0882029B1 Heterocyclic derivatives as antidiabetic and antiobesity agents |
| 04/02/2003 | EP0873295B1 Dimer-selective rxr modulators and methods for their use |
| 04/02/2003 | EP0847281B1 Method for detecting or monitoring the effectiveness of treatment of t cell mediated diseases |
| 04/02/2003 | EP0828481B1 Oral dosage composition comprising zonula occludens toxin and a biologically active ingredient and use thereof |
| 04/02/2003 | EP0566732B1 Adeno-associated virus-2 basal vectors |
| 04/02/2003 | CN1407990A C-aryl glucoside sgltz inhibitors |
| 04/02/2003 | CN1407985A Heterocyclic dihydropyrimidine as potassium path inhibitor |
| 04/02/2003 | CN1407984A 1,8-naphthyridin-2 (1H)-one derivatives |
| 04/02/2003 | CN1407983A Tert-butyl-(7-methyl-imidazo [1,2-A] pyridine-3-yl)-amine derivatives |
| 04/02/2003 | CN1407982A Serotonergic benzofurans |
| 04/02/2003 | CN1407980A Heterocyclic derivatives |
| 04/02/2003 | CN1407978A Polyhydroxystilbenes and stibene oxides as antisoriatic agents and protein kinase inhibitors |
| 04/02/2003 | CN1407975A Crystals of an oxyiminoalkanoic acid derivative and their use as antidiabetics |
| 04/02/2003 | CN1407971A Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof |